focus -WSS

focus

author：hotspot 2025-08-11 17:24:43 Page View：1

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Elisabeth Bik tackles the widespread issue of research misconduct
Next article： Hollywood unions extend contract negotiations for actors

focus

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

Childhood vaccination ad campaign launches in the U.K.

AyoungboyreceivesavaccineatahealthcenterinGlasgow,Scotland.JeffJMitchell/GettyImagesLONDON—Facingagr

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Pfizer is about to make a big push in cancer. Will investors listen?

PfizerCEOAlbertBourlaGiannisPapanikos/APPfizerhasabigproblem.Thedruggianthopesthatnewdrugstotreatcan

focus

explore

focus

Pfizer is about to make a big push in cancer. Will investors listen?